Effects of denosumab treatment in chronic liver disease patients with osteoporosis

Table 1 Baseline characteristics of the patients, n (%)

Variable	All patients (n = 60)
Age (yr)	74.0 (68.5–79.8)
Female	47 (78.3)
Menopause	47 (100)
BMI (kg/m2)	21.0 (19.2–23.6)
Etiology
HBV/HCV/PBC/Others	10/25/19/6
Liver cirrhosis	25 (41.7)
Child-Pugh A/B	21/4
Child-Pugh score	5 (5–6)
MELD score	3.0 (0.5–6.0)
Osteoporotic fracture	25 (41.7)
AST (U/L)	26 (20–28)
ALT (U/L)	15 (12–24)
ALP (U/L)	283 (235–332)
GGT (U/L)	24 (17–40)
Total bilirubin (mg/dL)	0.7 (0.5–0.9)
Platelet (× 104/μL)	16.6 (12.6–22.7)
Prothrombin time	98 (86–100)
Albumin (g/dL)	4.1 (3.9–4.4)
Creatinine (mg/dL)	0.7 (0.6–0.9)
eGFR (mL/min/1.73 m2)	64 (53–75)
Ca (mg/dL)	9.4 (9.1–9.7)
Pentosidine (μg/mL)	0.0584 (0.0475–0.0761)
TRACP-5b (mU/dL)	533 (358–661)
Total P1NP (ng/mL)	57 (44-80)
Lumbar spine BMD (g/cm2)	0.84 (0.76–0.94)
Lumbar spine T score	-2.41 (-1.28)–(-2.94)
Femoral neck BMD (g/cm2)	0.61 (0.56–0.66)
Femoral neck T score	-2.94 (-2.64)–(-3.32)
Total hip BMD (g/cm2)	0.67 (0.59–0.71)
Total hip T score	-2.48 (-2.07)–(-2.95)

Data are expressed as median (interquartile range) or number (percentage). Othrers (alcoholic liver disease, n = 4; autoimmune hepatitis, n = 1; nonalcoholic steatohepatitis, n = 1). ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMD: Bone mineral density; BMI: Body mass index; BP: Bisphosphonate; HBV: Hepatitis B virus; HCV: Hepatitis C virus; Egfr: Estimated glomerular filtration rate; GGT: Gamma-glutamyltransferase; MELD: Model for end-stage liver disease; P1NP: Procollagen type N-terminal propeptide; TRACP-5b: Tartrate-resistant acid phosphatase 5b; PBC: Primary biliary cholangitis.